by Raynovich Rod | May 28, 2019 | Biopharmaceuticals, Macro
Update-2 5/31 2:15 p EDT. Impossible to invest with current Tariff Headwinds-XBI down 1.24% to $79.83. NASDAQ down 1.33%. ========= Update-1 5/29… Better Tape Today Off Lows Despite 1.1% Drop in IBB and 0.93% in XBI One of our top picks from JPM was Amarin...
by Raynovich Rod | May 21, 2019 | Biopharmaceuticals, Macro
Update-2…3:15p EDT…. Mixed day-new post after close, XBI down 0.64%, IBB down 0.94%,, Dow sell-off down 0.43%. ====== Update-1 5/22… Not much follow-through from yesterday but trade-able.A horrible news week with politics, tariffs, chips and China...
by Raynovich Rod | May 5, 2019 | Biopharmaceuticals
Traders -look for a turnaround in small cap biopharma and medtech today. NAZ at 7890. 5/10 1:30p EDT….Well we know now that even biotech stocks are not immune to tariffs. Risk off. Major ETFS IBB at 104.5 and XBI near 84 are at intermediate support and off lows...
by Raynovich Rod | Apr 30, 2019 | Biopharmaceuticals
Biopharma Wrap-Up: Sideways to Neutral in Active Trading for Quarter Biopharma stocks ended the quarter in a snooze as investors took a wait and see attitude as earnings roll-out for large caps. The IBB was off 0.83% today to $106.42 and up 9% QTD. The XBI is still up...
by Raynovich Rod | Sep 4, 2018 | Biopharmaceuticals
Update: 10:10a Tesaro (TSRO) Soars 15% to $38, short covering or bargain hunters? News item: expansion of Zejula Combo Trial in NSCLC ========= Biotech Weakness in Large Caps Mid-Caps Have Continued Strength The overall market recovered from an early sell-off but...
by Raynovich Rod | Jul 7, 2018 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biotech Momentum Boosted by Biogen’s Experimental Drug Biogen Has an Interesting Pipeline of Medicines for Serious Neurological Diseases Broad Biotech Rally-Green Screen Day- Even Large Caps Biotech momentum picked up on Friday after a brief sell-off in late...
by Raynovich Rod | Jun 30, 2018 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
Biotech Bull Market: Up 25.39% Over 2 Years With High Volatility XBI Outperforms Up 12% YTD; FBT is Comparable, IBB lags. Three Funds did well in H1 2018 (7-9%). Biotech stocks peaked in July 2015 and reached a bottom on 10/31/16 gradually clawing their way back to a...
by Raynovich Rod | Jun 21, 2018 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Momentous Biotech for June Update 6/28…A nice broad rally on Friday included the large cap biotechs with the IBB up 1.73% to $109.82. Even Celgene (CELG) found buyers up 3.6% flirting with the $80 level. The big winner was Vertex (VRTX) up 15.16% to the $170...
by Raynovich Rod | Jun 10, 2018 | Biopharmaceuticals
Update-1 Gene Editing stocks are hit hard by a STAT Report that edited cells may cause cancer. Here is a later summary from STAT. As of 2:45 PDT trading; CRSP down 12% at $60, EDIT down 7.8% at $36.14. NTLA down 9.9% at $24.5. The report was published in Nature...
by Raynovich Rod | Jun 8, 2018 | Biopharmaceuticals
ASCO 2018 Rally Part 2: Traders Take Profits on Nice Gains Biotech Indices and ETFs Show Gains YTD: FBIOX up 8% YTD, IBB up 3.13%, XBI up 9.34% The ASCO 2018 biotech rally was almost according to the script-nice gains leading up to the meeting followed by momentum...